Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter W de Herder

Showing results (61-70 of 238) with videos related to

Pageof 24
Sort By:
Endocrine|November 12, 2022
Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature reviewCesar L Boguszewski, Márta Korbonits, Audrey Artignan, et al.
Endocrine-Related Cancer|September 17, 2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotateKimberly Kamp, Brenda Gumz, Richard A Feelders, et al.
Cancers|July 27, 2022
Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor MicroenvironmentThomas Cuny, Peter M van Koetsveld, Grégoire Mondielli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2007
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidneyEdgar J Rolleman, Peter P M Kooij, Wouter W de Herder, et al.
Hematology/Oncology Clinics of North America|June 6, 2007
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analoguesDik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursMartijn van Essen, Eric P Krenning, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic originMartijn van Essen, Eric P Krenning, Willem H Bakker, et al.
European Journal of Endocrinology|August 14, 2014
GEPNETs update: Radionuclide therapy in neuroendocrine tumorsWouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumorsMartijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Endocrine-Related Cancer|January 8, 2019
Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markersAura D Herrera-Martínez, Leo J Hofland, María A Gálvez Moreno, et al.
Pageof 24

Showing results (61-70 of 238) with videos related to

Sort By:
Pageof 24
Endocrine|November 12, 2022
Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature reviewCesar L Boguszewski, Márta Korbonits, Audrey Artignan, et al.
Endocrine-Related Cancer|September 17, 2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotateKimberly Kamp, Brenda Gumz, Richard A Feelders, et al.
Cancers|July 27, 2022
Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor MicroenvironmentThomas Cuny, Peter M van Koetsveld, Grégoire Mondielli, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2007
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidneyEdgar J Rolleman, Peter P M Kooij, Wouter W de Herder, et al.
Hematology/Oncology Clinics of North America|June 6, 2007
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analoguesDik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2008
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursMartijn van Essen, Eric P Krenning, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 30, 2007
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic originMartijn van Essen, Eric P Krenning, Willem H Bakker, et al.
European Journal of Endocrinology|August 14, 2014
GEPNETs update: Radionuclide therapy in neuroendocrine tumorsWouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2010
Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumorsMartijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Endocrine-Related Cancer|January 8, 2019
Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markersAura D Herrera-Martínez, Leo J Hofland, María A Gálvez Moreno, et al.
Pageof 24